How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

GLP-1 battle heats up again as Novo claws its way back into race with Lilly

The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market